1. Home
  2. MDB vs UTHR Comparison

MDB vs UTHR Comparison

Compare MDB & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MongoDB Inc.

MDB

MongoDB Inc.

HOLD

Current Price

$264.83

Market Cap

30.0B

Sector

Technology

ML Signal

HOLD

Logo United Therapeutics Corporation

UTHR

United Therapeutics Corporation

HOLD

Current Price

$572.31

Market Cap

25.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MDB
UTHR
Founded
2007
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
30.0B
25.1B
IPO Year
2017
1999

Fundamental Metrics

Financial Performance
Metric
MDB
UTHR
Price
$264.83
$572.31
Analyst Decision
Buy
Buy
Analyst Count
34
14
Target Price
$368.67
$567.57
AVG Volume (30 Days)
1.5M
570.3K
Earning Date
06-03-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
49.13
13.07
EPS
N/A
27.86
Revenue
N/A
$1,483,300,000.00
Revenue This Year
$18.88
$7.08
Revenue Next Year
$17.14
$14.32
P/E Ratio
N/A
$21.12
Revenue Growth
N/A
2.38
52 Week Low
$149.01
$272.18
52 Week High
$444.72
$607.89

Technical Indicators

Market Signals
Indicator
MDB
UTHR
Relative Strength Index (RSI) 53.07 56.34
Support Level $256.65 $464.92
Resistance Level $266.50 $607.89
Average True Range (ATR) 13.23 16.71
MACD 5.25 -1.17
Stochastic Oscillator 91.25 44.07

Price Performance

Historical Comparison
MDB
UTHR

About MDB MongoDB Inc.

Founded in 2007, MongoDB is a vendor of a document-oriented database that accelerates development processes of new applications. Enterprise customers can choose between the fully managed offering, MongoDB Atlas, or the self-managed version, MongoDB Enterprise Advanced. MongoDB is a popular tool among developers, and its free Community Server has recorded over 500 million downloads since 2009.

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.

Share on Social Networks: